These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33283981)

  • 41. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
    Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T
    Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study.
    Akizawa T; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Yamamoto H
    Ther Apher Dial; 2021 Dec; 25(6):917-925. PubMed ID: 33506635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.
    Hou YP; Mao XY; Wang C; Xu ZH; Bu ZH; Xu M; Li B
    J Formos Med Assoc; 2022 Feb; 121(2):529-538. PubMed ID: 34167878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
    Besarab A; Chernyavskaya E; Motylev I; Shutov E; Kumbar LM; Gurevich K; Chan DT; Leong R; Poole L; Zhong M; Saikali KG; Franco M; Hemmerich S; Yu KH; Neff TB
    J Am Soc Nephrol; 2016 Apr; 27(4):1225-33. PubMed ID: 26494833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and Efficacy of Vadadustat Once Daily and Three Times Weekly in Patients With Dialysis-Dependent CKD With Anemia.
    Kooienga L; Burke S; Kathresal A; Luo W; Yang Z; Zhang Z; Zwiech R; Hernandez GT
    Kidney360; 2024 Nov; 5(11):1652-1661. PubMed ID: 39231617
    [No Abstract]   [Full Text] [Related]  

  • 48. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
    Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Clinical Parameters in Patients with Heart Failure.
    Yazaki M; Nabeta T; Takigami Y; Eda Y; Fujita T; Iida Y; Ikeda Y; Ishii S; Ako J
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256345
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: a multicenter prospective study in Japan.
    Hattori M; Uemura O; Hataya H; Ito S; Hisano M; Ohta T; Fujinaga S; Kise T; Gotoh Y; Matsunaga A; Ito N; Akizawa T;
    Clin Exp Nephrol; 2014 Aug; 18(4):634-41. PubMed ID: 24013765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
    Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
    Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N; Wish JB
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
    Nephron; 2019; 143(2):77-85. PubMed ID: 31117088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis.
    Zabaneh R; Roger SD; El-Shahawy M; Roppolo M; Runyan G; O'Neil J; Qiu P
    Perit Dial Int; 2015; 35(4):481-9. PubMed ID: 24584613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.
    Nangaku M; Hamano T; Akizawa T; Tsubakihara Y; Nagai R; Okuda N; Kurata K; Nagakubo T; Jones NP; Endo Y; Cobitz AR
    Am J Nephrol; 2021; 52(1):26-35. PubMed ID: 33561857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation.
    Wish JB; Eckardt KU; Kovesdy CP; Fishbane S; Spinowitz BS; Berns JS
    Am J Kidney Dis; 2021 Nov; 78(5):709-718. PubMed ID: 34332007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
    Doggrell SA
    Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.